amikacin sulfate / Generic mfg. - LARVOL DELTA

Luciferase reporter mycobacteriophage (TM4::GeNL) enables rapid assessment of drug susceptibilities and inducible macrolide resistance in Mycobacterium abscessus complex. (PubMed, J Clin Microbiol) - "Mycobacterium abscessus (MAB) infections are challenging to treat due to high-level resistance to anti-tuberculosis drugs, carbapenems, fluoroquinolones, and tetracyclines. Clarithromycin and amikacin are considered cornerstone drugs for MAB treatment due to their superior efficacy; however, assessing clarithromycin susceptibility typically takes 7 to 14 days because of inducible macrolide resistance...All clarithromycin-resistant isolates carried full-length inducible erythromycin ribosomal methylase-41 [erm(41)] gene, and none had rrl (23S rRNA) mutations...In addition, LRM-DST results for bedaquiline, moxifloxacin, imipenem, linezolid, and cefoxitin correlated well with Sensititre DST...We developed a novel luciferase reporter mycobacteriophage (LRM) based phenotypic DST method using TM4::GeNL to assess MAB drug susceptibility based on metabolic inhibition rather than growth. LRM-DST significantly reduces the DST turnaround time to 48 h and provides rapid assessment..."

Journal • Cystic Fibrosis • Genetic Disorders • Immunology • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Adverse effects associated with Kanamycin, Amikacin, Capreomycin and Bedaquiline -a VigiAccess™ study. (PubMed, Afr Health Sci) - "Therefore, VigiAccess™ provides a good platform for reporting and awareness of specific adverse effects associated with MDR-TB therapy. This is a vital stepping stone for further research."

Adverse events • Journal • Dermatology • Infectious Disease • Otorhinolaryngology • Pruritus • Pulmonary Disease • Respiratory Diseases • Tuberculosis

MIKA: Research of the Consequences on the Digestive Tract Following the Proposed Treatments for a Urinary Infection in Children (clinicaltrials.gov) - P=N/A | N=200 | Recruiting | Sponsor: Centre Hospitalier Intercommunal Creteil | Trial completion date: Jan 2025 ➔ Jul 2026 | Trial primary completion date: Jan 2025 ➔ Jul 2026

Trial completion date • Trial primary completion date • Infectious Disease • Nephrology • Urology

First Case of Nocardia seriolae Infection in China Cultured Channel Catfish (Ictalurus punctatus). (PubMed, J Fish Dis) - "Drug sensitivity testing indicated susceptibility to commonly used antibiotics such as co-trimoxazole, doxycycline, enrofloxacin, florfenicol, amikacin and rifampicin. 100% mortality with 1 × 108, 1 × 107 and 1 × 106 cfu/mL in a 35-d challenge test period was observed, and the intraperitoneal injection median lethal dose (LD50) was 1.89 × 104 cfu/mL. This is the first isolation report of N. seriolae infection from cultured channel catfish, aiming to warn against the continuous host-range expansion of this pathogen, which is threatening the inland aquaculture industry."

Journal • Hepatitis C • Immunology • Infectious Disease • Inflammation • Sarcoidosis • AFF4

Child-Turcotte-Pugh score-based modified anti-tubercular treatment in patients with decompensated cirrhosis with tuberculosis: A two-year retrospective observational study from North India. (PubMed, Indian J Gastroenterol) - "As per our study, patients with decompensated cirrhosis tolerated the CTP-score-based modified ATT and almost 80% had a resolution of tuberculosis."

Journal • Observational data • Retrospective data • Fibrosis • Hepatology • Immunology • Infectious Disease • Liver Failure • Pulmonary Disease • Respiratory Diseases • Tuberculosis • RELA

Whole-genome sequencing and machine learning reveal key drivers of delayed sputum conversion in rifampicin-resistant tuberculosis. (PubMed, Front Cell Infect Microbiol) - "Univariate analysis linked 2-month SCC failure to smear positivity, resistance to isoniazid, amikacin, capreomycin, and levofloxacin, and pre-XDR-TB status, though only smear positivity (aOR=2.41, P=0.008) and levofloxacin resistance (aOR=2.83, P=0.003) persisted as independent predictors in multivariable analysis. A Random Forest model achieved robust prediction of SCC failure (AUC: 0.86 ± 0.06 at 2 months; 0.76 ± 0.10 at 6 months), identifying levofloxacin resistance (feature importance: 6.37), embB_p.Met306Ile (5.94), and smear positivity (5.12) as top 2-month predictors, while katG_p.Ser315Thr (4.85) and gyrA_p.Asp94Gly (3.43) dominated 6-month predictions. These findings underscore smear positivity, levofloxacin resistance, and specific resistance mutations as critical drivers of SCC failure, guiding targeted RR-TB treatment strategies."

Journal • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Recurrent Small Bowel Obstruction Secondary to Intestinal Tuberculosis: A Case Report and Review of the Literature (ACG 2025) - "A nasogastric tube was placed and the patient was started on IV rifampin, levofloxacin, amikacin, and linezolid...Intestinal TB may be difficult to diagnose as it can present similarly to pathologies such as intra-abdominal infection, IBD, or malignancy. Misdiagnosis rates of intestinal tuberculosis have been reported to be as high as 50-70%, even in countries with a high prevalence of tuberculosis."

Case report • Clinical • Review • Gastrointestinal Disorder • Hepatology • Infectious Disease • Respiratory Diseases • Tuberculosis

Hospital acquired drug resistant pathogens infections in patients with viral respiratory tract infections: a retrospective study. (PubMed, BMC Infect Dis) - "The drug resistance rate of P. aeruginosa to third-generation cephalosporins (such as ceftriaxone and cefotaxime) exceeds 89%, but it has relatively higher sensitivity to ceftazidime (71.7%) and cefepime (69.6%)...pneumoniae shows resistance rates of 53.3% to imipenem and 46.7% to meropenem, with over 50% resistance to levofloxacin and ciprofloxacin. Effective agents include sulfamethoxazole (68.9% susceptible), tigecycline (64.4%), chloramphenicol (62.2%), and amikacin (62.2%)...baumannii was highly resistant to nearly all tested antibiotics, showing only partial susceptibility to minocycline (59.5%) and trimethoprim-sulfamethoxazole (38.1%). Among the seven ML models, the neural network (NN) achieved the best predictive performance. The SHAP method revealed the top 15 predictive variables by importance ranking, including length of stay (LOS), cholinesterase (CHE), age, albumin (ALB), etc."

Journal • Retrospective data • Infectious Disease • Influenza • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

Dynamic injectable photothermal/chemotherapeutic hydrogel for prevention and treatment of local wound infections. (PubMed, J Biomater Appl) - "Herein, a dynamic injectable photothermal/chemotherapeutic hydrogel has been facilely established through mixing gellan gum (GG), indocyanine green (ICG) and amikacin (AMI) aqueous solutions at 80°C and cooling to room temperature...These exceptional physicochemical properties and combined effects of chemotherapy and PTT facilitated the satisfactory in vitro biocompatibility and antibacterial capability as well as wound healing acceleration ability. Therefore, such a dynamic injectable photothermal/chemotherapeutic hydrogel paves the way toward easily clinical transformation for prevention and treatment of local wound infections."

Journal • Infectious Disease

Clinical features, antimicrobial susceptibilities, treatment characteristics and outcomes of paediatric Acinetobacter lwoffii bacteremia: a case series. (PubMed, Eur J Clin Microbiol Infect Dis) - "Acinetobacter lwoffii remains an important pathogen of hospital-acquired bacteraemia in hospitalised children. Treatment with broad-spectrum beta-lactam antibiotics, either as monotherapy or combined with amikacin or colistin, appears effective."

Journal • Infectious Disease • Pediatrics

Six-year antimicrobial resistance patterns of Escherichia coli isolates from different hospitals in Gaza, Palestine. (PubMed, BMC Microbiol) - "The resistance pattern of E. coli varies depending on gender, age, and specimen sources, and this should be taken into account when treating E. coli infections."

Journal • Infectious Disease

Under Pressure: Granulomatous Liver Disease and Portal Hypertension in Disseminated MAC (ACG 2025) - "The patient was discharged on ethambutol, rifabutin, azithromycin, and IV amikacin. Fig 3. High-power (400X mag) Ziehl-Neelsen stain highlights abundant acid-fast bacilli."

Candidiasis • Cardiovascular • Fibrosis • Hepatology • Human Immunodeficiency Virus • Immunology • Infectious Disease • Inflammation • Portal Hypertension

Leclercia adecarboxylata Bacteremia in a Patient With Ulcerative Colitis (ACG 2025) - "The organism was sensitive to ceftriaxone and amikacin. The present case supports the hypothesis that the patient's active UC was the likely source of bacteremia. Literature suggests that UC and other inflammatory GI conditions increase the risk of invasive infections due to gut bacterial translocation."

Clinical • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • CRP

Investigation of carbapenemase-encoding genes in Burkholderia cepacia and Aeromonas sobria isolates from nosocomial infections in Iraqi patients. (PubMed, PLoS One) - "Piperacillin, cefepime, and ceftriaxone showed antimicrobial resistance of 100%, followed by ceftazidime (97.3%), cefazolin (96%), and piperacillin/ tazobactam (94.6%). Intermediate resistance was reported with aztreonam (61.3%), meropenem (49.3%), trimethoprim-sulfamethoxazole (49.3%), gentamicin (46.6%), levofloxacin (44%), and ciprofloxacin (44%). It is important to note minocycline (40%), amikacin (40%) imipenem (36%) and tigecycline (34.6%), had the lowest resistance rates, hence their relatively higher efficacy against the tested isolates...Since the prevalence of carbapenemase producers is high, careful infection control measures, rapid diagnostics, and antimicrobial stewardship must be implemented by clinicians. It is necessary that combination therapy be guided and early detectable to ensure better outcomes and restrict resistance."

Journal • Infectious Disease • Thermal Injury

THE HIDDEN INVADER: ATYPICAL MYCOBACTERIUM FORTUITUM PULMONARY INFECTION IN PEOPLE LIVING WITH HIV (MTS 2025) - "Initial treatment comprised two months of IV amikacin, levofloxacin, and oral linezolid, followed by oral levofloxacin and doxycycline for prophylaxis, with a total treatment duration of at least 12 months post-sputum culture clearance...Effective management requires timely, integrated clinical, radiological, and microbiological evaluation. Treatment involves prolonged multidrug therapy, with early intervention being key to improving outcomes."

Anemia • Bronchiectasis • Hematological Disorders • Human Immunodeficiency Virus • Infectious Disease • Nontuberculous Mycobacterial Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

P3MA: A Promising Mycobacteriophage Infecting Mycobacterium abscessus. (PubMed, Antibiotics (Basel)) - "All these results suggest that, after genetic engineering, P3MA could be a promising candidate for phage therapy in combination with imipenem, including lung infections."

Journal • Infectious Disease • Respiratory Diseases

Genomic Insights of Emerging Multidrug-Resistant OXA-48-Producing ST135 Proteus mirabilis. (PubMed, Antibiotics (Basel)) - "It exhibited a multidrug-resistant phenotype, being susceptible only to amikacin and ceftazidime/avibactam. The emergence of blaOXA-48 among P. mirabilis strains of the international clone ST135 in different geographical regions is worrying. Close monitoring of these strains is required in One Health settings."

Journal

Outbreak Caused by VIM-1- and VIM-4-Positive Proteus mirabilis in a Hospital in Zagreb. (PubMed, Pathogens) - "This study revealed an epidemic spread of carbapenemase-producing P. mirabilis in two wards in a psychiatric hospital. Due to the extensively resistant phenotype (XDR), therapeutic options were limited. This is the first report of carbapenemase-producing P. mirabilis in Croatia."

Journal • Infectious Disease • Psychiatry

Aminoglycosides: an update on indications, dosing and monitoring. (PubMed, Aust Prescr) - "Aminoglycosides (gentamicin, tobramycin and amikacin) are highly effective parenteral drugs commonly used as initial empirical therapy of serious Gram-negative infections. The guidelines now recommend that dosing in adults is based on lean body weight, and provide calculators to assist with dose calculations. Therapeutic drug monitoring is required when aminoglycoside therapy is expected to continue beyond 48 hours; monitoring the area under the aminoglycoside concentration-time curve is recommended in adults."

Journal • Review • Infectious Disease

Nocardia otitidiscaviarum meningitis in an immunocompetent patient diagnosed by metagenomic next-generation sequencing: a case report. (PubMed, Front Med (Lausanne)) - "Ceftriaxone was initially employed as an anti-infective agent, however, it was ineffective. Consequently, the treatment was escalated to a combination of meropenem and vancomycin, yet the patient's condition did not significantly improve...Following this diagnosis, the patient's condition was rapidly controlled after initiating treatment with the targeted drug combination of sulfamethoxazole, meropenem, and amikacin. Given the high misdiagnosis rate and poor sensitivity of cultures for Nocardia otitidiscaviarum in cases of intracranial infections, this case underscores the critical role of mNGS in the diagnosis and selection of effective antibiotics for treating Nocardia intracranial infections."

Biomarker • Journal • Next-generation sequencing • CNS Disorders • Infectious Disease

Molecular analysis and ceftazidime-avibactam susceptibilities of carbapenem-resistant Klebsiella pneumoniae: Seven year experience from blood cultures of liver transplant recipients in a university hospital. (PubMed, Diagn Microbiol Infect Dis) - "The presence of the OXA-48 resistance gene in CRKP isolates was closely associated with in vitro susceptibility to CZA, regardless of the diversity of the patient population."

Journal • Infectious Disease • Pneumonia • Septic Shock • Transplantation

Comparative effectiveness of prophylactic antibiotic regimens in preventing infection in open fractures: a prospective cohort study. (PubMed, BMC Musculoskelet Disord) - "Participants were grouped by clinician-selected regimens: Group A (Cefazolin 1 g every 6 h + amikacin), Group B (Cefazolin 2 g every 8 h + amikacin), and Group C (Vancomycin 2 g every 12 h + amikacin). No abstract available"

HEOR • Journal • Dermatology • Infectious Disease • Musculoskeletal Diseases • Orthopedics

Synergistic action between peptide-neomycin conjugates and polymyxin B against multidrug-resistant gram-negative pathogens. (PubMed, Front Microbiol) - "The combination of aminoglycosides and colistin is often used to treat pneumonia caused by multidrug-resistant bacteria...Most A. baumannii strains are resistant to amikacin, gentamicin, tobramycin, and plazomicin, and approximately half are susceptible to neomycin...Resistance to the combination of R-, C-, or RC-NEO conjugates and PB did not develop over a 14-day period in neomycin-susceptible strains of A. baumannii, K. pneumoniae, and P. aeruginosa. Based on this survey of the peptide-neomycin library, circumvention of aminoglycoside-modifying enzymes and alluding to bacterial resistance is an important step toward the design and development of peptide aminoglycoside-based motifs for antimicrobial drug development."

Journal • Infectious Disease • Pneumonia • Respiratory Diseases

Therapeutic application of a jumbo bacteriophage against metallo-β-lactamase producing Pseudomonas aeruginosa clinical isolates. (PubMed, J Biomed Sci) - "The newly reported Phikzvirus jumbo phage AttikonH10 demonstrated a broad host range, strong lytic activity and synergistic effects with amikacin against MBL-PA isolates making it a candidate for phage therapy."

Journal • Infectious Disease

Combining Plant Bioactives With Antibiotics for Enhanced Antibiofilm Activity Against Uropathogenic Staphylococcus spp. and Cytotoxicity Evaluation. (PubMed, Adv Pharmacol Pharm Sci) - "The best synergistic combinations against biofilm inhibition and eradication were C1: cefixime (5.33 µg/mL) + thymol (32 µg/mL); C2: cefazolin (1.16 µg/mL) + thymol (21.33 µg/mL); C3: amikacin (0.18 µg/mL) + curcumin (37.33 µg/mL); C4: kanamycin (0.25 µg/mL) + curcumin (14 µg/mL); and C5: amoxicillin (1.16 µg/mL) + curcumin (21.33 µg/mL). While this study demonstrates promising in vitro results, further in vivo validation is necessary to confirm the efficacy and safety. Additionally, mechanistic studies are needed to understand the synergistic pathways, and future research should address scalability and formulation for clinical use."

Journal • Infectious Disease • Nephrology